Exploring the link between inhaled corticosteroids and respiratory infection

Symposium
Chairs: N. Lorent (Leuven, Belgium), T. Welte (Hannover, Germany)
Aims: to discuss emerging data concerning the role of inhaled corticosteroids in respiratory infections; to review the impact of inhaled corticosteroids on the risk of infection in the era of triple therapy, the impact of inhaled corticosteroids on the lung microbiome and how inhaled corticosteroids may increase susceptibility to viral-induced exacerbations of COPD.

Impacts of inhaled corticosteroids on antiviral and antibacterial immunity in the lung A. Singanayagam (London, United Kingdom)
Inhaled corticosteroids, bacterial load and the lung microbiome in COPD T. Wilkinson (Southampton (Hampshire), United Kingdom)
Inhaled corticosteroids and the increased risk of non-tuberculous mycobacteria infection S. Brode (Toronto (ON), Canada)
What do new data concerning triple therapy tell us about the risk of infection? M. Han (Ann Arbor, United States of America)